Fragile X Syndrome – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Fragile X Syndrome – Pipeline Review, H2 2019’, provides an overview of the Fragile X Syndrome pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Fragile X Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Fragile X Syndrome and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Fragile X Syndrome

– The report reviews pipeline therapeutics for Fragile X Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Fragile X Syndrome therapeutics and enlists all their major and minor projects

– The report assesses Fragile X Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Fragile X Syndrome”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Fragile X Syndrome

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Fragile X Syndrome pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“Advanced Medical Projects

Anavex Life Sciences Corp

Autifony Therapeutics Ltd

Confluence Pharmaceuticals LLC

DRI Biosciences Corp

Epigen Biosciences Inc

GlaxoSmithKline Plc

GW Pharmaceuticals Plc

Healx Ltd

Lysogene SAS

Marinus Pharmaceuticals Inc

Neuren Pharmaceuticals Ltd

Neuron Biopharma SA

Neurotrope Bioscience Inc

Novartis AG

Ovid Therapeutics Inc

Prous Institute for Biomedical Research SA

Sage Therapeutics Inc

Sentinel Oncology Ltd

Seropeutics LLC

Takeda Pharmaceutical Co Ltd

Tetra Therapeutics

Zynerba Pharmaceuticals Inc”

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Fragile X Syndrome - Overview 6

Fragile X Syndrome - Therapeutics Development 7

Fragile X Syndrome - Therapeutics Assessment 15

Fragile X Syndrome - Companies Involved in Therapeutics Development 23

Fragile X Syndrome - Drug Profiles 32

Fragile X Syndrome - Dormant Projects 118

Fragile X Syndrome - Discontinued Products 120

Fragile X Syndrome - Product Development Milestones 121

Appendix 130

List of Tables

“List of Tables

Number of Products under Development for Fragile X Syndrome, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Fragile X Syndrome – Pipeline by Advanced Medical Projects, H2 2019

Fragile X Syndrome – Pipeline by Anavex Life Sciences Corp, H2 2019

Fragile X Syndrome – Pipeline by Autifony Therapeutics Ltd, H2 2019

Fragile X Syndrome – Pipeline by Confluence Pharmaceuticals LLC, H2 2019

Fragile X Syndrome – Pipeline by DRI Biosciences Corp, H2 2019

Fragile X Syndrome – Pipeline by Epigen Biosciences Inc, H2 2019

Fragile X Syndrome – Pipeline by GlaxoSmithKline Plc, H2 2019

Fragile X Syndrome – Pipeline by GW Pharmaceuticals Plc, H2 2019

Fragile X Syndrome – Pipeline by Healx Ltd, H2 2019

Fragile X Syndrome – Pipeline by Lysogene SAS, H2 2019

Fragile X Syndrome – Pipeline by Marinus Pharmaceuticals Inc, H2 2019

Fragile X Syndrome – Pipeline by Neuren Pharmaceuticals Ltd, H2 2019

Fragile X Syndrome – Pipeline by Neuron Biopharma SA, H2 2019

Fragile X Syndrome – Pipeline by Neurotrope Bioscience Inc, H2 2019

Fragile X Syndrome – Pipeline by Novartis AG, H2 2019

Fragile X Syndrome – Pipeline by Ovid Therapeutics Inc, H2 2019

Fragile X Syndrome – Pipeline by Prous Institute for Biomedical Research SA, H2 2019

Fragile X Syndrome – Pipeline by Sage Therapeutics Inc, H2 2019

Fragile X Syndrome – Pipeline by Sentinel Oncology Ltd, H2 2019

Fragile X Syndrome – Pipeline by Seropeutics LLC, H2 2019

Fragile X Syndrome – Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019

Fragile X Syndrome – Pipeline by Tetra Therapeutics, H2 2019

Fragile X Syndrome – Pipeline by Zynerba Pharmaceuticals Inc, H2 2019

Fragile X Syndrome – Dormant Projects, H2 2019

Fragile X Syndrome – Dormant Projects, H2 2019 (Contd..1), H2 2019

Fragile X Syndrome – Discontinued Products, H2 2019”

List of Figures

“List of Figures

Number of Products under Development for Fragile X Syndrome, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Number of Products by Top 10 Targets, H2 2019

Number of Products by Stage and Top 10 Targets, H2 2019

Number of Products by Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports